PLAAT1: Key Enzyme in Lipid Metabolism and Potential Drug Target

Target Name: PLAAT1

NCBI ID: G57110

PLAAT1

PLAAT1: Key Enzyme in Lipid Metabolism and Potential Drug Target

PLAAT1 (Phospholipase A and acyltransferase 1, transcript variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a key enzyme in the lipid metabolism, which is the process by which the body produces and uses energy.

PLAAT1 is involved in the breakdown of lipids, which is essential for the production of energy and the maintenance of cellular health. It is a potent enzyme that breaking down the most abundant type of fat in the body, which is triglycerides. PLAAT1 helps to remove the phospholipid from the surface of the lipid molecules, which allows them to be internalized into the cell.

ThePLAAT1 gene has four splice variants, which are thePLAAT1 transcript variant 1, PLAAT1 transcript variant 2, PLAAT1 transcript variant 3, and PLAAT1 transcript variant 4. These variants are produced by alternative splicing of the gene's RNA, which means that they produce different proteins with different amino acid sequences.

PLAAT1 has been shown to play a role in various cellular processes, including the regulation of inflammation, metabolism, and cell signaling. For example, PLAAT1 has been shown to be involved in the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. It has also been shown to play a role in the regulation of cellular energy metabolism, by breaking down the lipids that are released during cellular energy storage.

PLAAT1 is also a potential drug target. Researchers have identified several potential small molecules that can inhibit PLAAT1 activity, which may be useful for treating various diseases. For example, some studies have shown that inhibiting PLAAT1 can reduce the production of pro-inflammatory cytokines, which may be useful for treating autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.

Another potential application of PLAAT1 is as a biomarker for certain diseases. The breakdown of lipids is a critical process for the body, and changes in the level of PLAAT1 activity in certain tissues, such as the liver and muscle, can be an indication of certain diseases. For example, increased PLAAT1 activity in the liver has been shown to be associated with the development of certain types of cancer.

In conclusion, PLAAT1 is a protein that is involved in various cellular processes, including the regulation of inflammation, metabolism, and energy storage. It is also a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of PLAAT1 in these processes and to develop effective treatments for the associated diseases.

Protein Name: Phospholipase A And Acyltransferase 1

Functions: Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:21880860, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:21880860, PubMed:22825852, PubMed:27623847). Shows O-acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:21880860). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE) which serves as precursor for N-acylethanolamines (NAEs) (PubMed:21880860, PubMed:22825852, PubMed:27623847)

The "PLAAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLAAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets